SARAF

Across TCGA pan-cancer cohorts, SARAF mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SARAF data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SARAF mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SARAF expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where SARAF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.887	0.283	.012	8	view →
HNSC	OS	Quartile	III,IV	0.140	1.000	.038	7	view →
LUAD	OS	Tertile	All	0.873	1.000	.024	7	view →
OV	DFS	Median	All	0.818	1.000	.015	4	view →
PDAC	DFS	Tertile	IV	0.752	0.199	.024	3	view →
LSCC	OS	Median	II,III,IV	0.753	0.914	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SARAF–CCRCC (DFS)

Open the CCRCC breakdown →